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Background: Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation and
inflammation. Meanwhile, COPD also is associated with metabolic disorders, such as skeletal muscle weakness.
Strikingly, activation of AMP-activated protein kinase (AMPK) exerts critical roles in energy metabolism. However,
it remains unclear whether and how the expression levels of AMPK are affected in the COPD model rats which
may lead to the dysfunction of the skeletal muscle in these rats.
Methods: Here we developed a rat model of COPD, and we investigated the morphological changes of peripheral
skeletal muscle and measured the levels of tumor necrosis factor -α (TNF-α) and AMPK in skeletal muscle by using
approaches that include immunohistochemistry and polymerase chain reaction (PCR).
Results: We found that the expression levels of both AMPK mRNA and protein in skeletal muscles were significantly
reduced in the COPD model rats, in comparison to those from the control rats, the COPD model rats that received
treatments with AICAR and resveratrol, whereas the expression levels of TNF-α were elevated in COPD rats.
Conclusion: Such findings indicate that AMPK may serve as a target for therapeutic intervention in the treatment
of muscle weakness in COPD patients.Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by a kind of airflow limitation that is not fully
reversible [1]. The airflow limitation is usually progressive
and associated with an abnormal inflammatory response
of the lungs [2]. However COPD is also associated with
comorbidities such as metabolic diseases, sleep apnea,
anemia, weight loss and skeletal muscle weakness. In ac-
cording to the World Health Statistics report (2013) that
these comorbidities are progressively increasing healthcare
burden and hospital admission, which lead to a reduced
health status and increasing mortality in addition to the
dysfunction of lung. It is reported that COPD currently is
the fourth leading cause of death in the world, and will
rise to the third leading cause of death by 2030 [3]. Fur-
thermore, it has been well recognized that the dysfunction
of skeletal muscle is an independent predictive factors
leading to death [4]. Skeletal muscle weakness is reflected* Correspondence: zgj@zzu.edu.cn
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unless otherwise stated.by the reduced muscle strength and endurance, as well as
the increased muscle fatigability [5]. Muscle weakness is
mainly observed in the lower limb muscle of patients with
COPD [6]. For instance, quadriceps muscle weakness is a
common feature in patients at all stages of COPD [7,8].
During the period of acute exacerbations of COPD, the
strength of upper limb muscles is also noticed to be re-
duced [9]. With the development of COPD,the perfor-
mances of lower extremity muscles include (i) muscle
fiber type shifting from type I towards type IIx muscle
fibers which results in reduced oxidative and fiber at-
rophy; (ii) increasing glycolytic capacity; (iii) loss of
muscle mass; and (iv) decreased capillary density. Col-
lectively, it will be a useful predictor for mortality in
patients with COPD [10].
Meanwhile, recent studies suggest that systemic in-
flammation exerts critical roles in the development of
COPD. Clinical studies demonstrate that COPD patients
have apparent skeletal muscle dysfunction, in addition to
the difficulties in breathing. However, the relationship
between energy metabolism and the inflammation impli-
cated in COPD patients remains unclear. In COPD pa-
tients,the serum levels of several inflammatory mediatorsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[12], IL-6, IL-8, IL-18 [13], and acute phase reactants
[14]. In the COPD patients who are hospitalized due to
acute exacerbations, the serum levels of IL-8 are increased
and also negatively associated with the weakness in the
quadriceps. It has been indicated that pharmacological ac-
tivation of AMPK, e.g. by AICAriboside (AICAR), exerts
negative influential effects on the inflammatory processes
through increasing the release and/or the production of
anti-inflammatory cytokines. It has also been shown that
activation of AMPK can increase macrophage phagocyt-
osis. Conversely, the obesity and/or LPS treatment-based
reduction of the AMPK activities leads to the increase in
the pro-inflammatory responses, which may precede insu-
lin resistance. It is also reported that inhibition of inflam-
mation may result in more healthy aging and prolonged
life [15]. Meanwhile, AMPK is a key sensor and/or regula-
tor of cellular energy. Once activated, AMPK switches on
the catabolic pathways to generate adenosine triphosphate
(ATP) whereas AMPK switches off the biosynthetic path-
ways that consume ATP. Thus, the ATP levels are elevated
when the AMPK is activated. Because the cellular energy
status is a crucial factor for the cells to exert their diverse
functions in all aspects of cell function, it is not surprising
that AMPK has umpteen downstream targets whose
phosphorylation mediates dramatic changes in cell metab-
olism, cell growth, and other functions. Pharmacological
activation of AMPK by metformin holds a therapeutic po-
tential to reverse metabolic abnormalities such as type-2
diabetes and nonalcoholic fatty liver disease. However, it
remains unclear about the functional roles for the AMPK
activities in the skeletal muscle dysfunction complicated
with COPD. Therefore, to address these issues, we estab-
lished the COPD model rats. We observed morphological
changes of peripheral skeletal muscle as well as the abnor-
malities of mitochondria in skeletal muscle in these COPD
rats. We also measured the expression levels of TNF-α
and AMPK in the skeletal muscle in COPD rats, and
found that the treatments with resveratrol and/or AICAR
prevented the reduction of the AMPK levels in COPD rats
in comparison to those in the control rats. Collectively,
these results suggest that AMPK may help develop thera-




Hongqi Canal cigarettes (tobacco type of tar: 14 mg, nico-
tine content: 1.2 mg carbon monoxide fumes: 15 mg)
were from Henan tobacco industry limited liability com-
pany; LPS and AICAR were purchased from Sigma. Bo
compound resveratrol capsules Litas (LTL; Shanghai);
TNF-α ELISA kit from PeproTech; AMPKα1 rabbit anti-
mouse antibodies and the secondary antibodies werepurchased from Santa Cruz. Phospho-AMPKα1 (Ser485)
rabbit antibodies were purchased from ABGENT. SirT1
(D1D7) rabbit mAb was purchased from Cell Signaling
Technology.Animal treatment
Male Wistar rats (200 ± 20 g) were purchased from Henan
Experimental Animal Center (Zhengzhou). These animals
were housed in a temperature- and humidity-controlled
condition and kept on a 12 hr/12 hr light/dark cycle, with
free access to regular chow and water. Rats were ran-
domly divided into four groups with fifty rats per group,
as described below: control group, COPD + saline group,
COPD+AICAR group and COPD + resveratrol group.Preparation of COPD model rat
Experimental protocol was approved by the Experimental
Animal Care and ethics committee in the First Affiliated
Hospital, Henan University of Traditional Chinese Medicine,
Zhengzhou, China. The detailed procedures about COPD
model rats were described in the previous report [16].
Briefly, the rats were anesthetized using intraperitoneal in-
jection of ketamine (100 mg/kg), and were administered
with lipopolysaccharide (LPS) twice through intratracheal
instillation on Day 1 (0.2 ml in 1 mg/mL) and Day 15
(0.1 ml in 1 mg/ml) during the procedures. The rats were
exposed to tobacco (Hongqi Canal®Filter tip cigarette, to-
bacco type, tar: 10 mg, nicotine content: 1.0 mg, carbon
monoxide: 12 mg, Henan Tobacco Industry, Zhengzhou,
China) smoke of 8 cigarettes per treatment, twice a day,
during the first two weeks; then fifteen cigarettes per treat-
ment, three times per day, from week 3 through week 12.
The rats were placed in a sealed box connected to smoke
source to receive two or three times of 30 min exposures
per day, at the interval of one or two 3 hr. Control rats
were exposed to the air following the similar procedures
as described immediately above.Administrations
Starting from Day 29, two COPD rats were sacrificed
to evaluate if the model was successfully made on the
basis of the pathological changes of lung histology
and pulmonary functional impairment. The rest rats
received control saline and/or chemicals as grouped
below: (i) Control group (2 ml of 0.9% saline, intra-
gastriceally, once a day for 30 days); (ii) COPD model
group (2 ml of 0.9% saline, intragastriceally, once a day for
30 days); (iii) COPD model group that received AICAR
(AICAR; 250 mg/kg, subcutaneously, once a day for
30 days); (iv) COPD model group that received res-
veratrol (Resveratrol, 100 mg/kg, intragastrically, once
a day for 30 days).
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At the end of the treatments for each rat, lung and skeletal
muscle tissues were sampled after euthanasia and cut into
3-millimeter thick slices along the maximum diameter of
the right lower lobe and lower extremity and fixed them
in 4% paraformaldehyde (PFA) for 72 hours. The samples
were embedded with paraffin, and sections of the samples
were made in 4 μm thickness. Lung tissue stained with
hematoxylin and erosin (H & E) and skeletal muscle stained
with MASSON. All images were taken at amplification of
200 under an Olympus PM-10 AD optical microscope
and photographic system (Olympus, Tokyo, Japan).
Skeletal muscle ultrastructure morphology
The skeletal muscle tissues were cut into sections at the
thickness of 1-millimeter. The sections were fixed in glu-
taraldehyde for 2 hours, and then were post-fixed in 1%
osmium tetroxide, stained in uranyl acetate, dehydrated
in a methanol series and propylene oxide, and embedded
in epoxy resin. The sections at 70 nm in thickness were
stained with uranyl acetate and lead. The muscle fila-
ment arrangement, muscle weakness and mitochondria
were analyzed by taking images of the sections using a
JEM-1400 transmission electron microscope and photo-
graphic system (Hitachi, Japan).
Estimate the TNF-α in serum and skeletal muscle
The level of TNF-α in serum and skeletal muscle tissue was
assayed by Enzyme-linked immunosorbent assay (ELISA)
in according to the instruction of the kits (PeproTech,
Rocky Hill, United States).
Real time fluorescence quantitative PCR of AMPKα1
For total RNA extraction, rat skeletal muscle (100 mg)
were dissolved in Trizol (1 ml) (Life Technologies, NY,
USA), and assessed by agarose gel electrophoresis and ab-
sorbance measurements at 260 and 280 nanometer (nm)
wavelength on SP-1901 ultraviolet light spectrophotom-
eter (Jinpeng Analytic Instrument Company, Shanghai,
China). The purification and integrity of the total RNA
were assayed. Reverse transcription (RT) was performed
by using Supre® III First-Strand Synthesis SuperMix for
qRT-PCR (Life Technologies, NY, USA). PCR was per-
formed by using Platinum SYBR® Green® Super Mix-UDG
Kit (Life Technologies, NY, USA). The reaction system
was prepared following the instructions of the kits. The
initial activation was at 95°C for 15 s, 60°C for 30 s,
40 cycle; and 95°C for 15 s, 60°C for 1 min, 95°C for 15 s,
60°C for 30 s (ABI, CA, USA). The relative quantity of
mRNA expression was assayed using 2-ΔΔCt formula.
The primers of AMPKα1 were designed and synthe-
sized by Generay Biotech Co. Ltd. (Shanghai, China).
The primer sequences of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) are: forward (5′-3′) gggtcagaaggattcctatg and reverse (5′-3′) ggtctcaaacatgatctggg;
and the primer sequences of AMPK are: forward (5′-3′)
cattcttggttgccgaaaca and reverse (5′-3′) tgtttggatttctg
tgggtt.
Western blotting of AMPKα1, p-AMPKα1, SIRT1 analysis
The skeletal muscle tissues were grinded into powder
using liquid nitrogen in a mortar. The tissue lysates were
collected into EP tube, and were centrifugated with
10000 r/min for 10 min in 4°C. The protein content in
the supernatant was measured using BCA (bicinchoni-
ninc acid), and the supernatant was stored at -70°C.
100 μg protein from each group of the samples were
assayed by SDS-PAGE electrophoresis, and the proteins
were transferred to PVDF membrane in a buffer con-
taining 5% skim milk for Tween 20-Tris HCl seal film
4 h at room temperature. The PVDF membrane was in-
cubated with the first antibody, mouse anti- AMPKα1,
phospho-AMPKα1(Ser485) antibody and Sirt1(D1D7)
rabbit mAb at room temperature for 1 h and then at 4°C
incubated for 24 h. After 5 min rinsing with 0.01 mol/L
Tween 20-Tris HCl buffer for three times, the PVDF
membrane was incubated with horseradish peroxidase-
labeled anti-mouse IgG secondary antibody for 1 h at
room temperature. The PVDF membrane was rinsed
with 0.01 mol/L Tween 20-Tris HCl buffer for 5 min
and repeated 3 times. The light emission absorbance of
hybridization was detected by using electrogenerated che-
milummesence (ECL) and assayed by quantitative image
analysis software.
Results
Reduction of body weight in COPD model rats
In comparison to the control rats, the body weight in
COPD model rats was gradually decreased (Figure 1),
suggesting that the status of energy metabolism was al-
tered in COPD model rats which was consistent with
the decrease in the body weight in COPD patient. Intri-
guingly, we also noticed that AICAR treatment pre-
vented the reduction in the body weight in the COPD
model rats while there were no significant changes of
the body weight in the COPD rats treated with resvera-
trol (Figure 1). Further studies will be needed to investi-
gate the underlying mechanism(s) of the reduction of
body weight in the COPD model rats.
Pathological changes in lung tissue
The outline of the lung in COPD model rats was en-
larged and looked pale on the surface of the lung. The
sections of the lung also showed flaky brown smoke
spots. As shown in Figure 2, the thickness of bronchiole
wall in the COPD model rats was higher than that in the
control rats at 20 weeks while the thickness of the alveo-










































Figure 1 Decrease of body weight in the COPD model rats. The body weight of the COPD model rats (filled circles in pink) (n = 13) was
significantly reduced, in comparison to the body weight in the control rats (filled circles in black) (n = 12). AICAR treatment (n = 13, filled
circles in red) prevented the reduction of body weight in the COPD model rats. **p < 0.01; student t test.
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in comparison to the thickness of the wall from the
COPD model rats that received the vehicle control saline
injections. Furthermore, the structure of the alveolar was
destructed as indicated by the extensive alveolar wall
thickening, alveolar rupturing and small blood vessel wall
thickening under light microscopy (Figure 2B). TheseFigure 2 Pathological changes of the lungs in control rats and CO
resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD ra
with resveratrol treatment. Amplification ×200. Scale bar, 20 μm.abnormalities were ameliorated with the treatment of ei-
ther AICAR (Figure 2C) or resveratrol (Figure 2D).
Abnormal morphological changes in skeletal muscle
tissue in COPD rats
Interestingly, we found that the skeletal muscle fibers
became atrophy in the COPD model rats, in comparisonPD model rats that were treated with vehicles, AICAR and/or
ts with vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats
A B
C D
Figure 3 Morphological changes of the skeletal muscle in control rats and COPD model rats that were treated with vehicles, AICAR or
resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD rats with vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats
with resveratrol treatment. Amplification ×200.
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there were more collagen depositions in the COPD
rats (Figure 3B). Importantly, we found that both res-
veratrol and AICAR decreased the depositions of col-
lagen in the skeletal muscle tissue in the COPD model
rats (Figure 3C and D). Furthermore, the number of
mitochondria in triceps tissue of COPD model ratsA
C
Figure 4 Pathological changes of the mitochondria in the control rats
resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD rats w
with resveratrol treatment. Amplification ×100 000.was reduced and the mitochondria became swelling
complicated with more vacuoles and the dissolved
endometrial and crest of the mitochondria (Figure 4B).
More importantly, both resveratrol and AICAR ame-
liorated the abnormal changes of mitochondria as
mentioned above in the COPD model rats (Figure 4C
and D).B
D
and COPD model rats that were treated with vehicles, AICAR or
ith vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats
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muscle in COPD rats
Next, we tested if the TNF-α levels were also affected
in the COPD model rats. We found that the levels of
TNF-α in both serum and skeletal tissue were signifi-
cantly increased in the COPD model rats in compari-
son to those in the control rats (Figure 5A). Interestingly,
the levels of TNF-α in either serum or skeletal muscle
tissue in the COPD model rats that were treated with
resveratrol and AICAR were lower than those in COPD
rats that received saline treatment (Figure 5), although
we also noticed that the levels of TNF-α in the AICAR-
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Figure 5 The levels of TNF-α in both serum and muscle tissue
were elevated in COPD model rats, and AICAR or resveratrol
treatment decreased the COPD-based TNF-α elevation.
TNF-α in serum (A; Control: n = 14, 154.70 ± 3.47; COPD/saline: n = 12,
378.09 ± 7.60; COPD/AICAR, n = 14, 248.00 ± 6.30; COPD/Resveratrol,
n = 12, 255.43 ± 9.40; ***F3, 51 = 181.12, p < 0.001 comparing to
the control group; ###F2, 37 = 87.64, p < 0.001 for COPD/AICAR
group or COPD/resveratrol group compared to the COPD/saline
group). TNF-α in skeletal muscle (B; Control: n = 14, 129.77 ± 3.15;
COPD/saline: n = 12, 330.56 ± 6.87; COPD / AICAR, n = 14, 212.37 ± 5.49;
COPD/Resveratrol, n = 12, 229.30 ± 7.64; ***F3, 51 = 197.94, p < 0.001;
###F2, 37 = 91.87, p < 0.001 for COPD/AICAR group or COPD/resveratrol
group compared to the COPD/saline group).treated with resveratrol (Figure 5), yet the mechanisms
need to be further studied.
The decreased expressions of AMPK in skeletal muscle
tissues in COPD rats
Next, we examined if the expression levels of AMPK and
p-AMPK were also affected in the COPD model rats, in
according to that AMPK plays crucial functional roles in
regulating energy metabolism [15]. We found that the ex-
pression levels of both AMPKα1 mRNA and protein in
the skeletal muscle were significantly decreased in the
COPD model rats, compared to those from the control
rats and the COPD rats that were treated with AICAR
and/or resveratrol (Figure 6A,B and C). As expected,
the expression levels of the active p-AMPK were also
significantly decreased in the COPD model rats and
recovered with the treatment of AICAR and/or res-
veratrol (Figure 6D). We also noticed that the content
of AMPKα protein in the resveratrol group was a lit-
tle lower than that in the AICAR group (P <0.05), and
further studies are needed to investigate the difference be-
tween them.
The decreased expression of SIRT1 in skeletal muscle
tissue in COPD rats
We next tested if the expression of SirT1 is also affected
in the COPD model rats. We found that the expression
levels of SIRT1 were slightly but not significantly de-
creased in COPD model rats. Meanwhile, we found that
the expression levels of SirT1 protein in the skeletal
muscle were significantly increased with the treatment
of AICAR and resveratrol (Figure 7).
Discussion
COPD is complicated with chronic inflammation that
exerts crucial functional roles in the development and
pathophysiology of COPD. Meanwhile, it has been rec-
ognized that the inflammation accompanying COPD
leads to the skeletal muscle dysfunction. Strikingly, the
skeletal muscle weakness has been recognized as one of
the predictors for mortality in moderate or severe COPD
patients [5]. The COPD-based dysfunctions of the skel-
etal muscle show the loss of body weight, decreased
body mass index, muscle weakness and the decreased
endurance, as well as the decreased resistance to fatigue.
Previous studies demonstrated that systemic inflammation
could exert influential effects on the energy metabolism of
skeletal muscle [17], however it remains unknown that the
underlying mechanism(s) of the abnormal energy metab-
olism in COPD patients. Consistent with the COPD pa-
tients, we found that the COPD rats also behaved restless
and cough, as well as shortness in breathing at the early
stage of COPD within 8 weeks (data not shown). With the

































































































Figure 6 The expression of AMPK in muscle tissue was decreased in COPD model rats, and AICAR or resveratrol treatment recovered
AMPK expression in COPD model rats. (A) Sample blots of AMPK and β-actin. Normalized muscle AMPK mRNA (B; Control: n = 14; COPD/saline:
n = 12, 0.35 ± 0.04; COPD/AICAR, n = 14, 1.50 ± 0.12; COPD/Resveratrol, n = 12, 0.96 ± 0.05; ***F1, 25 = 68.31, p < 0.001 comparing the control group
to the COPD/saline group; **F1, 27 = 11.89, p = 0.002 comparing the control group to the COPD/AICAR group; ###F1, 23 = 74.98, p < 0.001 comparing
COPD/saline to COPD/resveratrol; ###F1, 25 = 60.98, p < 0.001 comparing COPD/saline to COPD/AICAR group). Normalized muscle AMPK protein
(C; Control: n = 14; COPD/saline: n = 12, 0.32 ± 0.03; COPD/AICAR, n = 14, 0.96 ± 0.04; COPD/resveratrol, n = 12, 0.66 ± 0.01; ***F1, 25 = 66.17,
p < 0.001 comparing the control group to the COPD/saline group; ***F1, 25 = 25.21, p < 0.001 comparing the control group to the COPD/resveratrol
group; n.s. F1, 27 = 0.16, p = 0.70 comparing the control group to the COPD/AICAR; ###F1, 25 = 31.52, p < 0.001 comparing COPD/saline to COPD/AICAR;
###F1, 23 = 24.58, p < 0.001 comparing COPD/saline to COPD/resveratrol group. n.s. (not significant). Normalized muscle p-AMPK protein (D; Control:
n = 6; COPD/saline: n = 6, 0.58 ± 0.14; COPD/AICAR, n = 6, 1.26 ± 0.30; COPD/resveratrol, n = 6, 1.29 ± 0.30; * F1, 11 = 5.1, p < 0.05 comparing the control
group to the COPD/saline group; ###F2, 17 = 15.15, p < 0.001 comparing COPD/saline to COPD/AICAR and COPD/resveratrol. n.s. F2, 17 = 0.093
comparing the control group to the COPD/resveratrol group and COPD/resveratrol. n.s. (not significant).
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and more deposition of collagen fibers in the skeletal
muscle in COPD rats (Figure 4). The morphology of
mitochondria was abnormal as well, as indicated by the
swelling, vacuolization, endometrial and damaged crest
in the skeletal muscle mitochondria (Figure 4). These
results indicated that the atrophy of skeletal musclecells and fibrosis did occur in the COPD model rats, sug-
gesting that the morphological abnormalities of mitochon-
dria underlie the dysfunctions of the skeletal muscle
energy metabolism partially explained why the COPD pa-
tients behave fatigue and decline in the exercise tolerance.
It has been well known that the TNF-α is a pro-
inflammatory factor, because some of the inflammatory


























Figure 7 AICAR and Resveratrol increased the expression of muscle SirT1 in muscle tissue in COPD model rats. Muscle SirT1 (Control:
n = 6; 0.55 ± 0.04; COPD/saline: n = 6, 0.44 ± 0.03; COPD/AICAR, n = 6, 0.73 ± 0.02; COPD/Resveratrol, n = 6, 0.73 ± 0.03). n.s. F1, 11 = 5.0, p = 0.051
comparing the control group to COPD/saline group. ***F2, 17 = 48.69, p < 0.001 comparing the COPD/saline group to COPD/AICAR and
COPD/resveratrol group respectively. n.s. (not significant).
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For example, previous studies indicated that the inflam-
mation can be alleviated by inhibiting the activities of
TNF-α [18]. We found that the expression levels of
TNF-α in the peripheral blood were elevated in the
COPD rats, in comparison to that from the control rats.
Conversely, we also found that the expression levels of
TNF-α were significantly decreased in the COPD rats
that were treated with resveratrol or AICAR (Figure 5).
Moreover, the expression levels of TNF-α in skeletal
muscle were also significantly elevated in the COPD rats
(Figure 5). Collectively, these results indicate that the
lung inflammation complicated with the development
of COPD might lead to the inflammation in the periph-
eral skeletal muscle tissue, which leads to the dysfunctions
of the skeletal muscle. Meanwhile, it is reported that the
morphological and functional abnormalities in mitochon-
dria are mediated by the inflammation through a variety
of signaling pathways [19,20]. Of note, it is also reported
that AMPK regulates the functions of mitochondria,
yet the underlying signaling pathway remains unknown
[21]. Interestingly, our data indicated that the expression
levels of AMPKα1 mRNA and protein were signifi-
cantly reduced in the COPD model rats, in compari-
son to that from the control rats (Figure 6A,B and C).
Meanwhile, the expression levels of the active p-AMPK
were also significantly decreased in the COPD muscle
(Figure 6D). We also found that the expression levels
of muscular TNF-α and AMPK α1 were negatively corre-
lated. We did not see any significant changes in the
expression levels of SirT1 in COPD rats (Figure 7), whichmay also be involved in muscular energy metabolism
[22]. AMPK is an important protein kinase in eukaryotic
cells and exerts crucial functions in energy metabol-
ism by the related metabolic enzymes [23,24]. Collect-
ively, these results thus suggest that the dysfunction of
skeletal muscular energy metabolism associated with the
systemic inflammation in COPD rats was probably caused
by decreasing the expression levels of AMPK although we
cannot exclude other signaling pathways.
Moreover, we found that treatment of the COPD model
rats with resveratrol or AICAR alleviated the morpho-
logical damage of mitochondria, in comparison to those in
COPD rats with saline treatments (Figure 4). Resveratrol
is a polyphenolic compound in grapes, red wine, purple
grape juice, peanuts, and some berries. Previous studies
indicated that resveratrol can reduce the release of proin-
flammatory cytokines and improve the levels of glutathi-
one as well as reduce the MPO activity in lung tissue
to thereby reduce lung injury [25]. The expression levels
of TNF-α in peripheral blood and skeletal muscle are de-
creased in the COPD model rats with resveratrol or
AICAR treatment, suggesting that resveratrol or AICAR
might inhibit the inflammatory response in COPD rats. In
both cases, we found that the expression levels of AMPK
were significantly elevated in comparison to those in the
COPD model rats that received saline, suggesting that res-
veratrol or AICAR may thus indirectly enhance AMPK
activities through inhibiting the inflammatory response in
addition to their direct activation on AMPK. Meanwhile,
we also found that AICAR or resveratrol increased the ex-
pression levels of SirT1 in the COPD model rats (Figure 7).
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actively exert their roles in inflammation and metabolic
regulation [26]. Also, there is evidence indicating that
AMPK and SirT1 regulate each other and share some
signaling pathways [27]. For instance, down-regulation
of p-AMPK reduces the levels of SirT1 [28]; on the other
way, SirT1 is required for moderate concentration of res-
veratrol to stimulate AMPK [29]. Based on our data, we
propose that the changes of AMPK activities contribute to
the dysfunctions of muscle metabolism in COPD rats, al-
though we cannot exclude the possibility that SirT1 and
other signaling are implicated in the modulation of mus-
cular metabolism.
In summary, in according to the previous studies and
our present findings, we proposed that in COPD model
rats TNF-α may probably inhibit the AMPK expression
in skeletal muscle. Meanwhile, resveratrol, as a new agent
to reduce the release of proinflammatory cytokines, play a
protective role in COPD. Therefore, AMPK may serve as
a potential therapeutic target for the treatment of muscle
weakness in COPD model rats.
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